


## PDE10A-IN-2 hydrochloride

<b>Cat. No.:</b>	HY-131973
<b>Molecular Formula:</b>	C <sub>33</sub> H <sub>38</sub> Cl <sub>3</sub> N <sub>5</sub> O
<b>Molecular Weight:</b>	627.05
<b>Target:</b>	Phosphodiesterase (PDE)
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (159.48 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		1.5948 mL	7.9738 mL	15.9477 mL
	5 mM		0.3190 mL	1.5948 mL	3.1895 mL
	10 mM		0.1595 mL	0.7974 mL	1.5948 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC<sub>50</sub> of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

PDE10A  
2.8 nM (IC<sub>50</sub>)

#### In Vivo

PDE10A-IN-2 hydrochloride (compound 14 3HCL; 2.5 mg/kg; oral administration; daily; for 3 weeks) treatment decreases the typical symptoms of PAH in rats<sup>[1]</sup>.

In Sprague-Dawley rats, the pharmacokinetic study of PDE10A-IN-2 hydrochloride (compound 14 3HCL; 10 mg/kg) shows the oral bioavailability up to ~50%, and the T<sub>1/2</sub> is 5.2 hours (p.o.), and the C<sub>max</sub> is 272 ng/mL<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wister rats (6 weeks, 160-180 g) injected with Monocrotaline <sup>[1]</sup>
Dosage:	2.5 mg/kg

---

Administration:	Oral administration; daily; for 3 weeks
Result:	Decreased symptoms of the pulmonary arterial hypertension (PAH) rats.

---

## REFERENCES

---

[1]. Yuncong Yang, et al. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharm Sin B. 2020 Dec;10(12):2339-2347.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA